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whom both agents were orally administered.
Patients and Methods: Eighteen recipients of allogeneic HSCT
who had already been on a steady dose of oral calcineurin inhibitors
(CsA (n5 8) or tacrolimus (n5 10)), and were started on oral
voriconazole (200 mg per body every 12 h) for the treatment or
prophylaxis of fungal infection could be evaluated. The concentra-
tion/dose (C/D; (ng/ml)/(mg/kg)) ratio of calcineurin inhibitors
was calculated 7–10 days after initiating voriconazole when the in-
creased blood levels of calcineurin inhibitors had stabilized. The
plasma level of voriconazole was measure by high-performance
liquid chromatography.
Results: The median C/D ratios of CsA and tacrolimus signif-
icantly increased after initiating voriconazole as compared with
those before initiating voriconazole (P\0.05). Median increases
of C/D ratios after initiating voriconazole were 62.0% with
a range of 0% to 135.8% in CsA-administered patients, and
196.8% with a range of -32.0% to 400.0% in tacrolimus-admin-
istered patients, which tended to be higher in tacrolimus-admin-
istered patients (P5 0.068). The plasma level of voriconazole
measured 7–10 days after initiating voriconazole was
2.266 1.21 mg/ml, and exceeded 2.0 mg/ml in 12 patients
(66.7%). The increase in C/D ratio of CsA and tacrolimus after
initiating voriconazole did not correlate with the plasma level of
voriconazole.
Conclusion:Although calcineurin inhibitors and voriconazole dem-
onstrates a significant interaction when both agents are administered
orally, the magnitude of interaction differs widely among the pa-
tients, and is considered greater with tacrolimus than with CsA.
Since the interindividual difference was not due to the difference
in the bioavailability of oral voriconazole, other mechanisms should
be explored.279
THE UPDATED SCHWARTZ FORMULA AS A SCREENING TEST FOR ABNOR-
MAL KIDNEY FUNCTION PRIOR TO HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Qayed, M., Thompson, A., Applegate, K., Haight, A., Chiang, K.-Y.,
Horan, J. Emory University and Children’s Healthcare of Atlanta, GA
Assessing renal function is an integral part of evaluating pedi-
atric patients for hematopoietic stem cell transplantation
(HSCT). The most accurate method is DTPA-Tc-99m GFR test-
ing. It, however, is costly and time consuming. The Schwartz
formula, which was recently updated, represents an easy alterna-
tive. To determine the appropriateness of using the updated and
simplified Schwartz formula for pre-transplant screening for ab-
normal kidney function, we compared it to the results obtained
using DTPA-Tc-99m GFR testing, which we routinely perform
as part of our pre-transplant evaluation. We retrospectively re-
viewed the charts of 107 consecutive children over the age of
12 months who underwent HSCT between January 1, 2004
and June 30, 2006, including demographic data, serum creatinine
and DTPA-Tc-99m GFR, height, and primary diagnosis. GFR
was estimated using the updated Schwartz formula (0.413*height
in centimeters/Creatinine). Nuclear medicine measurement of
GFR was carried out using DTPA-Tc-99m per institutional pro-
tocol, and calculated GFR was corrected for body surface area.
The utility of using the calculated GFR as a screening test to
distinguish patients with abnormal GFR (\90 ml/min/1.73 m2)
was tested by Receiver operating characteristic (ROC) curve anal-
ysis. Cut-off points optimizing sensitivity and simultaneously op-
timizing both sensitivity and specificity were determined. There
were 56 males and 51 females. The mean age at transplantation
was 9.1 years (+/-5.8). Eighty five (79.4%) patients had malignan-
cies (table I). The mean estimates of GFR with DTPA-Tc-99m
and the updated formula were 106.62 (S.E, 628.35) and 96.48
(S.E., 626.10), respectively. The area under the curve for calcu-
lated GFR was 0.71 (P5 0.001). The GFR value optimizing both
was 87.4 ml/min/1.73 m2, with sensitivity 67.5% and specificity
64.4% (34% of patients misclassified). At a cut point of109 ml/min/1.73 m2, the sensitivity was 82.5%, however the
specificity was compromised at only 30.2%. The updated
Schwartz formula is a poor screening method for abnormal kid-
ney function in HSCT candidates. Nuclear medicine testing
maybe indicated, especially in heavily pretreated patients.280
PSYCHOSOCIAL FACTORS AS MEASURED BY THE TRANSPLANT EVALUA-
TION RATING SCALE (TERS) PREDICT LENGTH OF HOSPITALIZATION
AND INFECTIOUS COMPLICATIONS FOLLOWING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speckhart, D.1, Bashey, A.1,2, Morris, L.E.1,2, Solomon, S.1,2, Berry, T.1,
Holland, H.K.1,2 1 Blood and Marrow Transplant Program at Northside
Hospital, Atlanta, GA; 2 Blood and Marrow Transplant Group of Georgia,
Atlanta, GA
Although psychological and social factors are recognized as
being important in the evaluation of patients for hematopoietic
stem cell transplantation (HSCT), no standard approach to psy-
chosocial assessment currently exists. In solid organ transplanta-
tion, psychosocial assessments have been integrated into the
selection of appropriate candidates, and certain psychosocial var-
iables, such as active substance abuse, have been shown to neg-
atively impact outcomes in solid organ transplant patients. To
determine whether similar factors impact outcomes in patients
undergoing HSCT, we prospectively conducted psychosocial as-
sessments on 155 consecutive patients undergoing autologous
HSCT primarily initiated in an outpatient setting. The relation-
ship between psychosocial variables, such as those assessed on
the Transplant Evaluation Rating Scale (TERS), and objective
outcomes, such as length of hospitalization and the number of
documented blood infections were evaluated. Based on the pa-
tient’s TERS score, each patient was stratified into one of
two groups (low/moderate risk (n5 134) vs. high risk (n5 21))
based on their predicted psychosocial risk for problems during
transplant. Although the two groups were similar in regards to
known pre-transplant prognostic factors such as age, perfor-
mance status, disease risk, and transplant type, there continues
to be a significant difference in the mean length of hospitaliza-
tion between patients who score low/moderate (10 days) and
those who scored high (16 days) on the TERS. Furthermore,
there was also a significant difference (p\.0001) in the total
number of blood infections per patient (48% of high risk pa-
tient had documented blood infections vs. 39% of low/moderate
risk patients had documented blood infections) based on their
TERS score. This data also revealed a significant difference in
the total number of blood infections over all between groups
(p\.0001). Although psychosocial factors appear to influence
a patient’s process during HSCT, it is not clear what particular
psychosocial factor most impacts these objective outcomes.
These findings suggest a strong correlation between pre-trans-
plant psychosocial risk factors and patient experiences in
HSCT.281
THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFU-
SION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC
CELL TRANSPLANTATION (HCT)
Wang, Z.1, Sorror, M.L.1,3, Leisenring, W.1,2,4, Schoch, G.1,2,
Maloney, D.1,3, Sandmaier, B.M.1,3, Storb, R.1,3 1 Fred Hutchinson Can-
cer Research Center, Seattle, WA; 2 Fred Hutchinson Cancer Research
Center, Seattle, WA; 3 School of Medicine, University of Washington, Se-
attle, WA; 4 School of Public Health and Community Medicine, University
of Washington, Seattle, WA
We retrospectively analyzed transfusion requirements within the
first 100 days among 503 allogeneic HCT recipients with hemato-
logical malignancies given nonmyeloablative conditioning. We
compared transfusion needs among recipients given grafts 1)
S262 Poster Session IIfrom related (n5 265) vs. unrelated donors (n5 238), and 2) from
ABO matched (n5 292) vs. ABO mismatched donors (n5 211);
and 3) analyzed the impact of ABO incompatibility on nonmyeloa-
blative HCT outcomes. Related recipients required less platelet
and red blood cell (RBC) transfusions compared to unrelated recip-
ients (P\0.0001 for both), with comparable median numbers of
transfused units. Major/bidirectionally ABO-mismatched recipients
required more RBC transfusions than ABO-matched recipients
(P5 0.006). Rates of graft rejection/failure, grades II-IV acute
and chronic GVHD, 2-year relapse and 3-year survivals were com-
parable among ABO-matched, minor-mismatched, and major/bidi-
rectionally mismatched recipients (P5 0.93, 0.72, 0.57, 0.36 and
0.17, respectively). Times to disappearance of anti-donor IgG
and IgM isohemagglutinins among major/bidirectionally ABO-
mismatched recipients were affected by magnitude of pre-HCT
titers (P\0.001 for both) but not by GVHD (P5 0.71 and 0.78,
respectively) and donor type (P5 0.40 and 0.35, respectively). In
addition, we compared overall transfusion needs among patients re-
ceived myeloablative (n5 1353) vs. nonmyeloablative HCT. We
confirmed that myeloablative recipients required more platelet
and RBC transfusions than nonmyeloablative recipients (both
P\0.0001). Myeloablative patients given PBSC required less
platelet transfusions (P\0.0001) than those given marrow while
RBC transfusions did not differ significantly. Limiting the compar-
ison to PBSC recipients given the two different conditionings did
not change our findings. In conclusion, nonmyeloablative recipi-
ents required fewer platelet and RBC transfusions. Among them,
both unrelated and major/bidirectionally ABO-mismatched recipi-
ents required more RBC transfusions. However, ABO incompati-
bility did not affect any of the nonmyeloablative HCT outcomes.
Furthermore, anti-donor isohemagglutinin titers at the time of
transplantation predicted the tempo of titer disappearance after
transplantation.282
THE COST OF HERPES ZOSTER AMONG HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS
White, R.R.1, Palmer, L.2, Johnson, B.H.2, Fowler, R.2 1 Merck & Com-
pany Inc; 2 Thomson Reuters (Healthcare) Inc
Introduction: Hematopoietic stem cell transplant (HSCT) recipi-
ents have a high incidence of herpes zoster (HZ) following transplant
surgery. The primary objective of this study was to estimate the in-
cremental medical resource utilization (RU) and costs associated
with HZ in this population for the 21 days prior through 3 months
after diagnosis with HZ.
Methods: The MarketScan Research Databases from Thomson
Reuters (1999-2007) were assessed to determine the incremental
medical RU and cost due to HZ. Cases were selected if they
had an ICD-9-CM diagnostic code for HZ (053.x) following
evidence of receiving a hematopoietic stem cell transplant and
matched 1:1 via propensity scores to HSCT controls without
HZ. Differences in selected treatment and clinical characteristics
were assessed using t-tests for continuous variables and chi-
square tests for categorical variables. A two-part model (logistic
regression/negative binomial generalized estimating equations)
was selected for multivariate analysis of incremental medical
RU and costs.
Results: Of the 204 HSCT case recipients identified, 21.1%
(n5 43) were hospitalized with HZ as the principle diagnosis
(0 for controls), 10.8% (n5 22) were diagnosed with ophthalmic
HZ, (0 for controls) and 15.7% (n5 32) with neurological im-
pairment due to HZ (0 for controls). There were no claims for
disseminated HZ or for the administration of IV acyclovir within
7 days of HZ diagnosis. There was no significant difference in
opportunistic infections between cases and controls (47 versus
43, p5 0.533). HSCT recipients with HZ had significantly
more medical RU in all categories (inpatient admissions, averagelength of stay, emergency room visits, number of outpatient
visits, number of other outpatient services, and out patient pre-
scriptions) compared to controls (p\0.01). HSCT recipients
with HZ also had significant incremental medical costs due to
HZ (See Table 1).
Conclusions: Herpes zoster has a significant impact on the health,
medical service use and medical costs for HSCT recipients. Future
advances for the treatment or prevention of HZ in HSCT recipients
should be given strong consideration to help alleviate this medical
burden.
Table 1. Herpes Zoster related Medical Costs for HSCT
Recipients
N Observed Adjusted*HSCTwith HZ 204 $14,424 $10,452
HSCTwithout HZ (controls) 204 $6,215 $5,661
Incremental Cost $8,209 $4,791
Lower 95% C.I. $4,558
Upper 95% C.I. $5,042*p\0.0001 for the adjusted incremental cost.283
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH
SEVERE COMBINED IMMUNODEFICIENCY AND DISSEMINATED BACIL-
LUS CALMETTE-GUeRIN INFECTIONS
Gouveia, R.V.1, Bonfim, C.M.S.2, Ginani, V.C.1, Zecchin, V.G.1,
Carlesse, F.1, Carvalho, C.R.1, Schmitz, J.1, Marconcini, J.F.1,
Porto, D.1, Duarte, A.1, Ribeiro, L.A.1, Felix, O.M.W.O.1,
Simo˜es, P.C.1, Silva, A.G.1, Petrilli, A.S1, Carvalho, B.3,
Pinto, M.M.3, Seber, A.1 1 Instituto de Oncologia Pediatrica, Sa˜o Paulo,
SP, Brazil; 2 Universidade Federal do Parana, Curitiba, PR, Brazil;
3 Universidade Federal de Sa˜o Paulo, SP, Brazil
In many countries tuberculosis is an important public health prob-
lem and early BCG vaccine is used to prevent severe forms of the dis-
ease. In these same countries, the diagnosis of severe combined
immunodeficiency (SCID) is usually delayed and children may
have disseminated BCG infection at the time they are referred to he-
matopoietic stem cell transplantation (HSCT). Our objective is to
describe the experience transplanting young children with SCID
and tuberculosis in two Brazilian institutions.
Methods: retrospective chart review.
Results:A total of 23 children with SCID had allogeneic transplants.
Three patients had received BCG vaccine and were treated with at
least three drugs to prevent dissemination. Nine patients had dissem-
inated Mycobacterium bovis infection, described in the table. Me-
dian age at transplant was 14 months (5-39), 6 were male. Patients
had matched sibling donor transplants (N5 2), matched father (1)
or haploidentical mother (1), 5/6 unrelated cord blood (4) or marrow
(1). The vaccine scar usually produced a very prominent skin lesion
that ulcerated and drained after engraftment. Patients also presented
with enlarged axillary and retroperitoneal lymphnodes and hepatic/
spleen lesions that became more visible on ultrasound, CT or MRI at
the time of hematological recovery. All patients were treated with at
least 5 drugs (streptomycin, isoniazid, rifampin, ethambutol, cipro-
floxacin, azithromycin or clarithromycin) for 1-2 years, until com-
plete resolution of all signs of the disease and complete
immunological recovery. Six patients are alive 0.5-11 years post
transplant.
Conclusion: BCG-infection is not a contraindication for
HSCT in SCID patients. Axillary adenopathy, hepatic and
spleen nodules are common at presentation. All clinical find-
ings worsen with engraftment and may slowly resolve after im-
munological recovery and prolonged therapy with multiple
antibiotics.
